Results 231 to 240 of about 11,127 (277)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies, 2022
CADTH recommends that Nucala should be reimbursed by public drug plans for the treatment of patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) if certain conditions are met. Nucala should only be covered to treat adult patients with severe CRSwNP who have polyps on both sides of the nose, have already had at least 1 ...
openaire +1 more source
CADTH recommends that Nucala should be reimbursed by public drug plans for the treatment of patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) if certain conditions are met. Nucala should only be covered to treat adult patients with severe CRSwNP who have polyps on both sides of the nose, have already had at least 1 ...
openaire +1 more source
The spectrum of therapeutic activity of mepolizumab
Expert Review of Clinical Immunology, 2019Introduction: The basis of the development of the anti-interleukin-5 monoclonal antibody mepolizumab was the acknowledgment of the crucial importance of this cytokine in promoting eosinophils production, activation, and survival, which is associated with the eosinophilic asthma phenotype, as well as with other disorders characterized by high levels of ...
Cavaliere, Carlo +7 more
openaire +5 more sources
The safety of mepolizumab for the treatment of asthma
Expert Opinion on Drug Safety, 2017Asthma is an airway disease characterized by airway inflammation. It is associated with significant morbidity, mortality, and costs to the healthcare system and society. Interleukin-5 (IL-5) was identified for its role in eosinophil development, maturation, and survival in tissues, which has been related to disease severity and airway eosinophilia ...
J M FitzGerald, E Leung, K Al Efraij
openaire +2 more sources
Pharmacological profile of mepolizumab
Vnitřní lékařství, 2023An elevated number of eosinophils have been implicated in several type 2 inflammatory chronic diseases that occur at various sites in the body. Over the past 20 years, our knowledge of diseases associated with increased numbers of eosinophils has advanced thanks to the development of drugs that can reduce or even eliminate eosinophils.
openaire +2 more sources
Mepolizumab treatment for asthma
Expert Opinion on Biological Therapy, 2012Five percent of asthmatics have severe symptoms despite high doses of inhaled (ICS) or additional oral corticosteroids (OCS): these patients have high morbidity, risk for asthma death, and account for half of asthma healthcare spending. A subgroup (20 - 40%) of these has persistent airway eosinophilia and frequent exacerbations.
openaire +3 more sources
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis
Immunotherapy, 2023Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a heterogeneous upper airway disease that is prevalent globally. Recent research into the molecular basis of the disease has led to the development of biologics as a new therapeutic option for severe and recalcitrant forms of CRSwNP.
Xuandao Liu +2 more
openaire +2 more sources
Mepolizumab for eosinophilic granulomatosis with polyangiitis [PDF]
Nature Reviews Rheumatology, 2017 Targeting IL-5 could improve outcomes and have steroid-sparing effects in the management of eosinophilic granulomatosis with polyangiitis. However, some questions remain about how this approach affects specific aspects of the disease.
openaire +2 more sources
Mepolizumab for severe eosinophilic asthma
Expert Review of Respiratory Medicine, 2013In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year.
openaire +3 more sources
An evaluation of mepolizumab for the treatment of severe asthma
Expert Opinion on Biological Therapy, 2019Introduction: Asthma is considered one of the most common chronic conditions globally, characterized by variable airflow obstruction and symptoms. Severe asthma is diagnosed when asthma control requires high-intensity therapy or continues to remain uncontrolled despite treatment.
Morjaria J. B. +4 more
openaire +3 more sources